a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4
Phase II Study to evaluate the response on two blocks of topotecan and carboplatin
Sarcoma, Soft Tissue
DRUG: Topotecan|DRUG: Carboplatin
Response according to RECIST criteria
Toxicity|Overall-Survival|Event-free-survival
Phase II study for patients with chemosensible soft tissue sarcoma stage IV in children and adolescents ; response according to RECIST criteria following two blocks of combination therapy consisting of Topotecan and carboplatin